Nothing Special   »   [go: up one dir, main page]

EA201591943A1 - Ингибиторы metap2 и способы лечения ожирения - Google Patents

Ингибиторы metap2 и способы лечения ожирения

Info

Publication number
EA201591943A1
EA201591943A1 EA201591943A EA201591943A EA201591943A1 EA 201591943 A1 EA201591943 A1 EA 201591943A1 EA 201591943 A EA201591943 A EA 201591943A EA 201591943 A EA201591943 A EA 201591943A EA 201591943 A1 EA201591943 A1 EA 201591943A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
modified
metap2 inhibitors
conjugated
polymer
Prior art date
Application number
EA201591943A
Other languages
English (en)
Other versions
EA033912B1 (ru
Inventor
Джон С. Петерсен
Джеймс Шанахан
Original Assignee
Синдевркс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Синдевркс, Инк. filed Critical Синдевркс, Инк.
Publication of EA201591943A1 publication Critical patent/EA201591943A1/ru
Publication of EA033912B1 publication Critical patent/EA033912B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к модифицированным или конъюгированным с полимером ингибиторам MetAP2. Настоящее изобретение относится также к способам, которые предотвращают, индуцируют, вызывают или увеличивают потери массы тела, лечения ожирения и/или лечения метаболического синдрома с применением модифицированного или конъгированного с полимером ингибиторов MetAP2. Настоящее изобретение относится также к способам улучшения чувствительности к инсулину и гликемической регуляции, снижения уровня инсулина и/или улучшения чувствительности к лептину с применением модифицированных или конъгированных с полимером ингибиторов MetAP2.
EA201591943A 2013-04-10 2014-04-09 ИНГИБИТОРЫ MetAP2 И СПОСОБЫ ЛЕЧЕНИЯ ОЖИРЕНИЯ EA033912B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361810468P 2013-04-10 2013-04-10
US201461925918P 2014-01-10 2014-01-10
PCT/US2014/033476 WO2014169026A1 (en) 2013-04-10 2014-04-09 Metap2 inhibitors and methods of treating obesity

Publications (2)

Publication Number Publication Date
EA201591943A1 true EA201591943A1 (ru) 2016-07-29
EA033912B1 EA033912B1 (ru) 2019-12-09

Family

ID=51686946

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591943A EA033912B1 (ru) 2013-04-10 2014-04-09 ИНГИБИТОРЫ MetAP2 И СПОСОБЫ ЛЕЧЕНИЯ ОЖИРЕНИЯ

Country Status (13)

Country Link
US (8) US9173956B2 (ru)
EP (2) EP2984085B1 (ru)
JP (4) JP6420314B2 (ru)
CN (2) CN105431426A (ru)
AU (1) AU2014250983B2 (ru)
BR (1) BR112015025892A2 (ru)
CA (1) CA2908993C (ru)
DK (2) DK3574922T3 (ru)
EA (1) EA033912B1 (ru)
ES (2) ES2902082T3 (ru)
HK (1) HK1216313A1 (ru)
MX (1) MX371095B (ru)
WO (1) WO2014169026A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828605C (en) 2010-05-25 2019-01-15 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
DK3574922T3 (da) * 2013-04-10 2021-12-06 Syndevrx Inc Modificerede eller polymerkonjugerede fumagillol-metap2-inhibitorer til anvendelse til forbedring eller reetablering af insulinfølsomhed
CN106432255A (zh) * 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
CA3005450A1 (en) 2015-12-10 2017-06-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
WO2017123603A1 (en) * 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
EP3870231A1 (en) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
CN114573476B (zh) * 2020-09-14 2024-06-11 广州药本君安医药科技股份有限公司 线性头尾二胺桥连化合物及在制备治疗糖代谢紊乱疾病药物中的应用
AU2023220104A1 (en) * 2022-02-16 2024-08-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Metap2 inhibitors and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803586A (en) 1953-06-29 1957-08-20 Abbott Lab ph control in production of fumagillin
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
SE8702550D0 (sv) * 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US20030220233A1 (en) * 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1999011272A1 (en) 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US6306819B1 (en) 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
EP1080732A4 (en) 1998-05-22 2004-08-25 Daiichi Seiyaku Co DRUG COMPOSITION
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
ID29943A (id) 1998-10-30 2001-10-25 Daiichi Seiyaku Co Senyawa dds dan metode pengukurannya
WO2001018080A1 (en) 1999-09-08 2001-03-15 School Of Pharmacy, University Of London Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US20070161570A1 (en) * 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1436286B1 (en) 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
AU2003215245A1 (en) 2002-02-15 2003-09-09 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
CA2480666C (en) 2002-04-11 2012-03-06 Children's Medical Center Corporation Tnp-470 polymer conjugates and use thereof
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040228831A1 (en) * 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
CN1922332B (zh) 2003-12-31 2013-06-12 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
WO2006080591A1 (en) * 2005-01-26 2006-08-03 Chong Kun Dang Pharmaceutical Corp. Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
US20080248030A1 (en) 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
US7629315B2 (en) * 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
AU2008268262C1 (en) 2007-06-26 2015-02-19 Children's Medical Center Corporation MetAP-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20090104210A1 (en) * 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
WO2009073445A2 (en) 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
US8586019B2 (en) 2008-05-22 2013-11-19 Ramot At Tel-Aviv University Ltd. Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
US20120004162A1 (en) * 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
TWI373345B (en) * 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital INHIBITION OF NOTCH FOR THE TREATMENT AND PREVENTION OF OBESITY AND METABOLIC SYNDROME
US20130266578A1 (en) * 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
US20130137831A1 (en) 2010-05-25 2013-05-30 John S. Petersen Optimized drug conjugates
CA2828605C (en) 2010-05-25 2019-01-15 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
SG190688A1 (en) 2010-11-09 2013-07-31 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
JP2013543899A (ja) * 2010-11-29 2013-12-09 ザフゲン，インコーポレイテッド ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療
US9328082B2 (en) * 2011-03-08 2016-05-03 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
DK3574922T3 (da) 2013-04-10 2021-12-06 Syndevrx Inc Modificerede eller polymerkonjugerede fumagillol-metap2-inhibitorer til anvendelse til forbedring eller reetablering af insulinfølsomhed
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
CA3005450A1 (en) 2015-12-10 2017-06-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
WO2017123603A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction

Also Published As

Publication number Publication date
EA033912B1 (ru) 2019-12-09
MX2015014329A (es) 2016-06-21
CN112494476A (zh) 2021-03-16
BR112015025892A2 (pt) 2017-07-25
EP2984085A1 (en) 2016-02-17
US20140308235A1 (en) 2014-10-16
WO2014169026A1 (en) 2014-10-16
ES2902082T3 (es) 2022-03-24
DK3574922T3 (da) 2021-12-06
US10010544B2 (en) 2018-07-03
CA2908993A1 (en) 2014-10-16
US20230048989A1 (en) 2023-02-16
US20200155545A1 (en) 2020-05-21
US20150374657A1 (en) 2015-12-31
JP2019023219A (ja) 2019-02-14
CA2908993C (en) 2023-05-23
CN105431426A (zh) 2016-03-23
JP6420314B2 (ja) 2018-11-07
AU2014250983A1 (en) 2015-10-29
JP2023082195A (ja) 2023-06-13
EP3574922B1 (en) 2021-09-15
JP2016519106A (ja) 2016-06-30
ES2749746T3 (es) 2020-03-23
US9750737B2 (en) 2017-09-05
US20180271856A1 (en) 2018-09-27
US20170326135A1 (en) 2017-11-16
EP3574922A1 (en) 2019-12-04
DK2984085T3 (da) 2019-10-21
MX371095B (es) 2020-01-16
US9433600B2 (en) 2016-09-06
EP2984085A4 (en) 2016-12-07
US20170028014A1 (en) 2017-02-02
US20160346244A1 (en) 2016-12-01
US11304944B2 (en) 2022-04-19
EP2984085B1 (en) 2019-07-17
AU2014250983B2 (en) 2019-04-11
US10588904B2 (en) 2020-03-17
US9757373B2 (en) 2017-09-12
US9173956B2 (en) 2015-11-03
JP2021091738A (ja) 2021-06-17
HK1216313A1 (zh) 2016-11-04

Similar Documents

Publication Publication Date Title
EA201591943A1 (ru) Ингибиторы metap2 и способы лечения ожирения
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
MY169328A (en) Compositions for the treatment of dry eye
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
CL2012002217A1 (es) Polipeptido aislado que comprende cuando menos un monómero de un solo dominio variable de un agente nb que se enlaza a dr5 humano; metodo para la prevencion y/o el tratamiento de un trastorno que se puede tratar mediante la mejora de la apoptosis celular.
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
CL2017002774A1 (es) Secuencias de uricasa mejorada y métodos de tratamiento
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
EA201491500A1 (ru) Способы лечения фиброза
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
GT201200345A (es) Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА